论文部分内容阅读
To evaluate the efficacy and safety of moxifloxacin monotherapy for treatment of complicated intra-abdominal infections.PubMed,EMBASE,Science Direct,Clinical-Trials.gov and Cochrane Central Register of Controlled Trials were searched to retrieve randomised controlled trials (RCTs) compared moxifloxacin monotherapy with other antibiotics in the treatment of complicated intra-abdominal infections from January 1999 to July 2011.A meta-analysis of all included randomised controlled trials was performed.Four randomised controlled trials including a total of 2444 patients with complicated intra-abdominal infections were included for meta-analysis.The results of the meta-analysis indicated that the moxifloxacin was associated with similar clinical cure rate (four RCTs,1934 patients,OR =0.80,95% CI:0.61,1.04,p=0.09),bacteriological success rates (four RCTs,1484 patients,OR =0.79,95% CI:0.59,1.05,p =0.11) and mortality (four RCTs,2227patients,OR =0.91,95% CI:0.45,1.83,p =0.79) compared with the control group.The overall incidence of adverse events of moxifloxacin was significantly higher than that in the control group (three RCTs,1367 patients,OR =1.33,95% CI:1.07,1.63,p =0.008),although the incidence of drug-related adverse events(three RCTs,1601 patients,OR =1.13,95% CI:0.69,1.85,p =0.63) and serious adverse events (three RCTs,1815 patients,OR =1.23,95% CI:0.59,2.60,p =0.58) were similar between the compared treatment groups.Moxifloxacin is an effective and relatively safe option for the treatment of patients with intra-abdominal infections.Moxifloxacin monotherapy has similar efficacy to combination therapy.